GRYSKA DAVID W — SEC insider filings
SEC reporting owner CIK 1202335. 41 insider filings on record with FilingPulse; latest filed 2026-10-05.
Transaction summary — filings shown
Covers all 41 filings on record, filed 2020-08-24 to 2026-10-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 6,000 shares, $38,855 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 21 legs across 12 filings — 414,500 shares, $7,672,585 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 82.
- Largest priced transaction: sale of 7,871 shares @ $173.25 ($1,363,651) in Seagen Inc., filed 2020-11-23.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Seagen Inc. (SGEN) | Director | 12 | — | 15 legs · 44,500 sh · $6,746,785 | 44 |
| PDL BIOPHARMA, INC. (PDLI) | Director | 8 | — | 6 legs · 370,000 sh · $925,800 | 6 |
| Definium Therapeutics, Inc. (DFTX) | Director | 6 | 2 legs · 6,000 sh · $38,855 | — | 7 |
| Forte Biosciences, Inc. (FBRX) | Director | 7 | — | — | 12 |
| AERIE PHARMACEUTICALS INC (AERI) | Director | 3 | — | — | 8 |
| GW PHARMACEUTICALS PLC (GWPH) | Director | 3 | — | — | 4 |
| Celcuity Inc. (CELC) | Director | 2 | — | — | 1 |
Insider filings — GRYSKA DAVID W
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-05 | 3 | Celcuity Inc. (CELC) | Holdings only — no transactions reported | EDGAR |
| 2026-10-05 | 4 | Celcuity Inc. (CELC) | Grant/award (A): 893 @ $0 | EDGAR |
| 2026-08-27 | 4 | Forte Biosciences, Inc. (FBRX) | Code (U): 5,940 · Disposition to issuer (D): 2,000 (derivative) · Disposition to issuer (D): 1,000 (derivative) · Disposition to issuer (D): 2,000 (derivative) · Disposition to issuer (D): 31,000 (derivative) · Disposition to issuer (D): 18,353 (derivative) | EDGAR |
| 2026-06-15 | 4 | Definium Therapeutics, Inc. (DFTX) | Grant/award (A): 4,666 @ $0 · Grant/award (A): 19,188 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Forte Biosciences, Inc. (FBRX) | Grant/award (A): 18,353 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Mind Medicine (MindMed) Inc. (MNMD) | Grant/award (A): 75,187 (derivative) @ $0 | EDGAR |
| 2025-03-21 | 4 | Forte Biosciences, Inc. (FBRX) | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2024-12-05 | 4 | Mind Medicine (MindMed) Inc. (MNMD) | Purchase (P): 2,500 @ $7.17 | EDGAR |
| 2024-08-26 | 4 | Mind Medicine (MindMed) Inc. (MNMD) | Purchase (P): 3,500 @ $5.98 | EDGAR |
| 2024-08-22 | 4 | Forte Biosciences, Inc. (FBRX) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | Mind Medicine (MindMed) Inc. (MNMD) | Grant/award (A): 16,506 (derivative) @ $0 | EDGAR |
| 2023-12-15 | 4 | Seagen Inc. (SGEN) | Disposition to issuer (D): 49,003 @ $229 · Disposition to issuer (D): 8,750 (derivative) · Disposition to issuer (D): 9,260 (derivative) · Disposition to issuer (D): 9,260 (derivative) · Disposition to issuer (D): 9,260 (derivative) · Disposition to issuer (D): 9,260 (derivative) · +5 more | EDGAR |
| 2023-09-20 | 4 | Forte Biosciences, Inc. (FBRX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-08-02 | 4 | Forte Biosciences, Inc. (FBRX) | Grant/award (A): 148,514 @ $1.01 | EDGAR |
| 2023-06-23 | 4 | Mind Medicine (MindMed) Inc. (MNMD) | Grant/award (A): 13,851 @ $0 · Grant/award (A): 37,594 (derivative) @ $0 · Grant/award (A): 13,131 (derivative) | EDGAR |
| 2023-06-02 | 4 | Seagen Inc. (SGEN) | Grant/award (A): 2,044 @ $0 | EDGAR |
| 2023-02-15 | 4 | Seagen Inc. (SGEN) | Option exercise (M): 8,750 @ $36.70 · Option exercise (M): 8,750 (derivative) @ $0 | EDGAR |
| 2023-01-12 | 4 | Forte Biosciences, Inc. (FBRX) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-11-21 | 4 | AERIE PHARMACEUTICALS INC (AERI) | Disposition to issuer (D): 11,495 @ $15.25 · Disposition to issuer (D): 1,996 @ $15.25 · Disposition to issuer (D): 7,800 (derivative) @ $1.98 · Disposition to issuer (D): 16,854 (derivative) @ $9.14 | EDGAR |
| 2022-11-15 | 4 | Seagen Inc. (SGEN) | Sale (S): 7,500 @ $129.10 | EDGAR |
| 2022-06-13 | 4 | AERIE PHARMACEUTICALS INC (AERI) | Grant/award (A): 6,245 @ $0 · Grant/award (A): 16,854 (derivative) @ $0 | EDGAR |
| 2022-05-17 | 4 | Seagen Inc. (SGEN) | Grant/award (A): 1,503 @ $0 · Grant/award (A): 3,676 (derivative) @ $0 | EDGAR |
| 2022-04-21 | 4 | Seagen Inc. (SGEN) | Option exercise (M): 1,794 @ $20.06 · Sale (S): 1,794 @ $143.32 · Option exercise (M): 1,516 @ $20.06 · Sale (S): 1,516 @ $144.17 · Option exercise (M): 690 @ $20.06 · Sale (S): 690 @ $145.08 · +3 more | EDGAR |
| 2022-02-09 | 4 | Seagen Inc. (SGEN) | Option exercise (M): 1,100 @ $20.06 · Sale (S): 1,100 @ $137.45 · Option exercise (M): 1,029 @ $20.06 · Sale (S): 1,029 @ $138.66 · Option exercise (M): 2,371 @ $20.06 · Sale (S): 2,371 @ $139.42 · +3 more | EDGAR |
| 2022-02-01 | 4 | Seagen Inc. (SGEN) | Option exercise (M): 850 @ $20.06 · Sale (S): 850 @ $121.69 · Option exercise (M): 2,553 @ $20.06 · Sale (S): 2,553 @ $122.43 · Option exercise (M): 883 @ $20.06 · Sale (S): 883 @ $123.39 · +6 more | EDGAR |
| 2022-01-19 | 4 | Seagen Inc. (SGEN) | Option exercise (M): 4,500 @ $20.06 · Sale (S): 4,500 @ $135.24 · Option exercise (M): 4,500 (derivative) @ $0 | EDGAR |
| 2021-06-21 | 4 | AERIE PHARMACEUTICALS INC (AERI) | Grant/award (A): 1,750 @ $0 · Grant/award (A): 7,800 (derivative) @ $0 | EDGAR |
| 2021-05-18 | 4 | Seagen Inc. (SGEN) | Grant/award (A): 1,402 @ $0 · Grant/award (A): 3,462 (derivative) @ $0 | EDGAR |
| 2021-05-07 | 4 | GW PHARMACEUTICALS PLC (GWPH) | Disposition to issuer (D): 35,208 (derivative) · Disposition to issuer (D): 22,464 (derivative) | EDGAR |
| 2021-02-24 | 4 | GW PHARMACEUTICALS PLC (GWPH) | Grant/award (A): 22,464 (derivative) @ $0 | EDGAR |
| 2020-12-31 | 4 | PDL BIOPHARMA, INC. (PDLI) | Sale (S): 20,000 @ $2.74 | EDGAR |
| 2020-12-17 | 4 | PDL BIOPHARMA, INC. (PDLI) | Sale (S): 75,000 @ $2.68 | EDGAR |
| 2020-12-09 | 4 | PDL BIOPHARMA, INC. (PDLI) | Option exercise (M): 66,050 @ $1.64 · Option exercise (M): 66,050 (derivative) @ $1.64 | EDGAR |
| 2020-12-04 | 4 | PDL BIOPHARMA, INC. (PDLI) | Sale (S): 75,000 @ $2.52 | EDGAR |
| 2020-11-24 | 4 | PDL BIOPHARMA, INC. (PDLI) | Sale (S): 50,000 @ $2.43 | EDGAR |
| 2020-11-23 | 4 | Seagen Inc. (SGEN) | Option exercise (M): 7,129 @ $19.02 · Sale (S): 7,129 @ $174.20 · Option exercise (M): 7,871 @ $19.02 · Sale (S): 7,871 @ $173.25 · Option exercise (M): 7,129 (derivative) @ $0 · Option exercise (M): 7,871 (derivative) @ $0 | EDGAR |
| 2020-11-20 | 4 | PDL BIOPHARMA, INC. (PDLI) | Option exercise (M): 60,000 @ $1.64 · Option exercise (M): 60,000 (derivative) @ $1.64 | EDGAR |
| 2020-11-19 | 4 | PDL BIOPHARMA, INC. (PDLI) | Sale (S): 100,000 @ $2.40 · Sale (S): 50,000 @ $2.39 | EDGAR |
| 2020-11-06 | 4 | Seagen Inc. (SGEN) | Sale (S): 4,500 @ $180.60 | EDGAR |
| 2020-09-16 | 4 | GW PHARMACEUTICALS PLC (GWPH) | Grant/award (A): 35,208 (derivative) @ $0 | EDGAR |
| 2020-08-24 | 4 | PDL BIOPHARMA, INC. (PDLI) | Grant/award (A): 25,826 @ $0 · Grant/award (A): 118,671 (derivative) @ $3.63 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1202335 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs